“…9 , in MCF-7 both compounds showed a better performance, measured as a decrease in the percentage of cell viability, than Gossypol, in a concentration-dependent manner without involving the cell number seeded; this finding is an outstanding insight into the probable mechanism of action conducted by 6 and 37 which points mainly to a probable Bcl-2 inhibition, reinforced for a GPER modulation, since, from the energetical analyzes yielded by in silico simulations over the two pharmacological targets, the affinity of both compounds is slightly more representative for GPER in comparison with Bcl-2 (< onefold), however, from the individual results analysis, 37 decreased cell proliferation in a better way than 6 probably due to the slightly finer binding energy of this ligand towards Bcl-2 as is possible to contrast it both docking calculations and molecular dynamics simulations. Astoundingly, MDA-MB-231 cancer cell were more sensitive to the assayed compounds than MCF-7 cells, owing largely to a over expression of Bcl-2 protein on MDA-MB-231 cell line 64 , 65 , added to a slight GPER expression that in a basal state, triggers proliferation and cancer cell survival 66 , 67 , although, from the individual results obtained for MCF-7 cancer cells, 37 depicted an IC 50 value significantly lower than Gossypol (18.66 vs. 65.67 μM, respectively), probably due to multiple effects of this ligand at inhibit both estrogen receptors (ERs α > β and GPER) and the anti-apoptotic protein Bcl-2, triggering a synergistic effect which leads to a best antiproliferative performance than showed by Gossypol, besides, we were unable to determine the IC 50 value for G-15, due to solubilization problems starting at a 20 μM concentration (Data not showed). The highlighted above place both compounds as potential therapeutic options against most aggressive cancer type TNCB (Triple-Negative Breast Cancer) represented by the two cancer cell lines assayed.…”